Fatigue Severity Scale

1. Abstract

The Fatigue Severity Scale (FSS) is one of the most widely utilized and psychometrically validated patient-reported outcome measures designed to quantify the disabling impact of fatigue in clinical and research populations. Originally developed by Krupp and colleagues in 1989, the instrument was formulated to differentiate fatigue related to clinical neurological and autoimmune conditions—most notably multiple sclerosis (MS) and systemic lupus erythematosus (SLE)—from non-clinical fatigue and depressive symptomatology. The FSS consists of 9 self-administered items evaluated on a 7-point Likert scale ranging from 1 (Strongly disagree) to 7 (Strongly agree). The global score represents the arithmetic mean across all nine items, yielding an index spanning from 1.0 to 7.0, wherein higher scores denote elevated fatigue severity and greater disruption of daily living; an established clinical cut-off score of ≥ 4.0 typically denotes clinically meaningful or severe fatigue.

Extensive psychometric investigations have affirmed the scale’s robust measurement properties across diverse pathological cohorts, including Parkinson’s disease, post-stroke syndromes, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), traumatic brain injury, and post-viral conditions. Internal consistency reliability is consistently high, with Cronbach’s α coefficients frequently reported between .88 and .95, and test-retest reliability intraclass correlation coefficients (ICC) ranging between .82 and .93 across stable intervals. Exploratory and confirmatory factor analyses predominantly corroborate an essentially unidimensional construct centered on physical functioning, task endurance, and the functional interference of fatigue on family, occupational, and social obligations. Due to its brevity, low respondent burden, and strong correlation with objective functional outcomes, the FSS remains a benchmark measurement standard in clinical trials, epidemiological surveys, and neuro-rehabilitation contexts worldwide.

2. Keywords

Fatigue Severity Scale, FSS, fatigue measurement, multiple sclerosis, systemic lupus erythematosus, psychometrics, patient-reported outcome measures, physical fatigue, functional disability, scale validation, clinical cut-off score, neuro-rehabilitation

3. Authors

The Fatigue Severity Scale was originally conceptualized and validated by a multidisciplinary team of neurologists, clinical psychologists, and immunologists at the State University of New York at Stony Brook and the National Institutes of Health (NIH):

• Lauren B. Krupp, MD: Department of Neurology, School of Medicine, State University of New York at Stony Brook, Stony Brook, NY; currently Professor of Neurology and Director of the Multiple Sclerosis Comprehensive Care Center at NYU Grossman School of Medicine.
• Nicholas G. LaRocca, PhD: Department of Neurology, State University of New York at Stony Brook, Stony Brook, NY; later Vice President of Health Care Delivery and Policy Research at the National Multiple Sclerosis Society.
• John Muir-Nash, PhD: Department of Neurology, School of Medicine, State University of New York at Stony Brook, Stony Brook, NY.
• Alfred D. Steinberg, MD: Cellular Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health, Bethesda, MD.

Subsequent cross-cultural adaptations and validation studies have been executed internationally, such as the Dutch adaptation by M. B. Rietberg, E. E. H. van Wegen, and G. Kwakkel (2010) within the Department of Rehabilitation Medicine at the VU University Medical Center, Amsterdam, Netherlands.

4. Purpose

Pathological fatigue is a pervasive, disabling, and multifaceted symptom characterized by an overwhelming sense of tiredness, exhaustion, and cognitive or physical depletion that is disproportionate to exerted effort and not relieved by standard periods of rest. Despite its ubiquity across chronic neurodegenerative, autoimmune, and metabolic disorders, fatigue remained historically neglected in clinical diagnostics due to challenges surrounding subjective operationalization and frequent confounding with clinical depression, motor weakness, and sleep disturbances.

The primary purpose of the Fatigue Severity Scale is to provide clinicians, clinical trialists, and behavioral researchers with a rapid, reliable, and standardized self-report metric designed to assess the disabling impact of fatigue on everyday physical, occupational, and psychosocial activities. Specifically, the FSS was constructed to:

• Differentiate pathological fatigue associated with chronic medical and immunological conditions from baseline fatigue experienced by healthy community populations.
• Quantify the degree to which fatigue impairs sustained physical functioning, diminishes motivation, and interferes with domestic, professional, and social obligations.
• Distinguish subjective fatigue from the neurovegetative symptoms of major depressive disorder, ensuring that physical lassitude is not inappropriately pathologized exclusively as an affective disturbance.
• Establish a responsive, objective trajectory of symptom fluctuation across longitudinal treatment regimens, pharmacological interventions (e.g., amantadine, modafinil), and behavioral interventions (e.g., cognitive behavioral therapy, graded exercise therapy).

In clinical practice, the scale assists in the early detection and profiling of fatigue in patients presenting with multiple sclerosis, systemic lupus erythematosus, stroke, Parkinson’s disease, post-polio syndrome, chronic kidney disease, and fibromyalgia. In translational clinical trials, the FSS functions as a pivotal primary or secondary endpoint to establish the therapeutic efficacy of disease-modifying therapies and fatigue-mitigating compounds.

5. Psychological Construct

The psychological and physiological construct assessed by the Fatigue Severity Scale is best understood as perceived fatigue severity and functional impairment. Unlike simple visual analogue scales (VAS) that merely measure the momentary biological intensity of tiredness, the FSS measures the pervasive behavioral manifestations and functional consequences of fatigue across a seven-day recall window. The construct reflects an interplay between perceived physical capacity, cognitive-behavioral drive, and social role execution.

Physical Disruption and Sustained Endurance

A primary core of the FSS operationalizes fatigue as an impediment to bodily output and physical endurance. Items such as “Fatigue interferes with my physical functioning” (Item 4) and “My fatigue prevents sustained physical functioning” (Item 6) evaluate the perceived collapse of motor maintenance. Individuals with neurological conditions often describe motor fatigue as a dramatic failure of central drive, in which prolonged physical activity induces an abrupt cessation of muscle activation. The construct reflects the patient’s subjective appraisal that physical tasks trigger premature, profound exhaustion (“Exercise brings on my fatigue”, Item 2; “I am easily fatigued”, Item 3).

Motivational and Behavioral Initiation

Fatigue is not exclusively peripheral or muscular; it exerts a profound influence on goal-directed actions and intrinsic motivation. Item 1 (“My motivation is lower when I am fatigued”) taps into the cognitive-motivational dimension of fatigue, commonly known as abulia or apathy-like diminution of effort. Within neurobiological models, this aspect corresponds to dysfunctions within the frontostriatal and basal ganglia circuits, which regulate cost-benefit computations regarding effort allocation.

Role Interference and Psychosocial Disability

The ultimate clinical manifestation of severe fatigue is its capacity to dismantle social and occupational functioning. The construct captured by Items 5, 7, 8, and 9 measures the broader societal burden experienced by the individual. Item 7 (“Fatigue interferes with carrying out certain duties and responsibilities”) and Item 9 (“Fatigue interferes with my work, family, or social life”) evaluate externalized functional disability. Item 8 (“Fatigue is among my three most disabling symptoms”) uniquely requires the patient to hierarchically rank fatigue relative to other debilitating symptoms (e.g., chronic pain, spasticity, paresis, sensory loss), providing a metric of the subjective primacy of fatigue in the overall disease presentation.

6. Theoretical Framework

The architectural foundation of the Fatigue Severity Scale is anchored in multidimensional biopsychosocial frameworks of chronic illness, integrating behavioral medicine, neuroimmunology, and disability theory.

The Biopsychosocial Model of Fatigue

The FSS was informed by the conceptualization that fatigue in medical illness is not merely an epiphenomenon of peripheral tissue pathology, but rather a complex, systemic experience shaped by central nervous system mechanisms, neuroendocrine dysregulation, and psychological appraisal. Pro-inflammatory cytokines (such as Interleukin-1, Interleukin-6, and Tumor Necrosis Factor-alpha) alter neurotransmitter metabolism and disrupt basal ganglia and hypothalamic neural circuitry, giving rise to subjective fatigue. Krupp et al. framed this phenomenon as a central subjective state that fundamentally degrades the individual’s capacity to initiate and sustain voluntary activity.

Distinction Between Fatigue and Depression

A foundational theoretical assumption driving Krupp and colleagues (1989) was the imperative separation between the construct of fatigue and that of depression. Historically, clinician-administered scales and self-reports for affective illness (such as the Beck Depression Inventory or Hamilton Depression Rating Scale) contained somatic sub-items measuring energy loss, which inflated depression scores in medically ill individuals. Krupp et al. posited that fatigue represents a discrete, primary neurological symptom that can exist independently of anhedonia, suicidal ideation, or pervasive affective dysphoria. The FSS was theoretically structured to emphasize physical functioning and daily activity disruption while deliberately eschewing classical cognitive-affective depressive markers, allowing clinicians to measure fatigue without contamination from affective psychopathology.

The Cognitive-Behavioral Model of Chronic Fatigue

Subsequent psychometric and clinical research integrates the FSS within cognitive-behavioral formulations of chronic illness (e.g., Vercoulen et al., 1996). In this model, while disease-related biological factors may trigger initial fatigue, behavioral responses (e.g., severe activity reduction, all-or-nothing boom-and-bust cycles) and cognitive appraisals (e.g., catastrophizing the sensation of physical exertion) maintain and amplify functional disability. The FSS effectively reflects the end-state of this pathway by quantifying the degree to which fatigue restricts daily behavioral engagement.

7. Validity

The Fatigue Severity Scale has been rigorously evaluated for construct, convergent, discriminant, and predictive validity across hundreds of clinical investigations worldwide.

Construct and Discriminant Validity

In the seminal validation study by Krupp et al. (1989), the FSS demonstrated outstanding discriminant validity. The mean score of healthy control subjects was 2.3 ± 0.7, which was significantly lower than the mean scores observed in patients with multiple sclerosis (4.8 ± 1.3, p < .001) and systemic lupus erythematosus (4.6 ± 1.2, p < .001). Subsequent studies in Parkinson’s disease, post-stroke fatigue, and traumatic brain injury have replicated this significant differentiation between healthy cohorts and clinical populations.

Discriminant validity concerning depression was also demonstrated: while FSS scores correlated moderately with depressive symptoms (typically r = .30 to .50), partial correlation analyses and multiple regression models established that FSS variance remains largely independent of Beck Depression Inventory scores. Patients with primary depression report high subjective fatigue, but their FSS profiles often differ in the weighting of physical limitation items compared to patients with systemic autoimmune and neurological diseases.

Convergent Validity

The convergent validity of the FSS is established via high correlations with other validated fatigue metrics and functional status questionnaires:

• Visual Analogue Scale for Fatigue (VAS-F): Correlations between FSS global scores and continuous VAS measures of fatigue typically range between r = .65 and .80 across MS and post-stroke populations.
• Modified Fatigue Impact Scale (MFIS): Strong convergent associations are noted between the FSS and the total score of the MFIS (r = .70 to .84), with the highest correlation observed against the MFIS Physical subscale.
• Health-Related Quality of Life (HRQoL): FSS scores demonstrate significant negative correlations with the Physical Component Summary (PCS) of the SF-36 Health Survey (r = −.55 to −.72), reflecting that elevated fatigue is directly linked to degraded physical quality of life.

Sensitivity to Change and Criterion Validity

The FSS possesses robust responsiveness to clinical improvement following successful pharmacological, physical therapy, and behavioral interventions. In clinical trials evaluating amantadine for MS fatigue, the FSS exhibited statistically significant shifts corresponding to objective clinician global impressions of improvement. Receiver operating characteristic (ROC) analyses routinely identify area-under-the-curve (AUC) parameters exceeding .85 for identifying clinically disabling fatigue using the standard cut-off of ≥ 4.0.

8. Reliability

The reliability of the Fatigue Severity Scale has been confirmed across diverse clinical trials, cross-cultural translations, and patient demographics.

Internal Consistency

In the original validation study by Krupp et al. (1989), the FSS displayed an internal consistency reliability coefficient (Cronbach’s α) of .88 for the combined sample, .81 for MS patients, and .89 for SLE patients. Subsequent validation studies spanning various languages and diagnostic populations have confirmed similarly high internal consistency:

• Dutch Validation (Rietberg et al., 2010): Reported a Cronbach’s α of .90 in patients with multiple sclerosis.
• Parkinson’s Disease (Friedman et al., 2010): Observed internal consistency ranging from α = .89 to .93.
• Post-Stroke Populations (Lerdal et al., 2005): Demonstrated Cronbach’s α values ranging from .88 to .94.
• Systemic Sclerosis and Rheumatic Diseases: Demonstrated Cronbach’s α values consistently between .91 and .95.

Corrected item-total correlations for all nine items typically exceed .50, indicating that each item contributes meaningfully to the common underlying construct.

Test-Retest Reliability

The temporal stability of the FSS is well documented across clinically stable populations over intervals ranging from several days to several weeks:

• Krupp et al. (1989) initially demonstrated significant stability across repeated administrations in healthy and clinical controls.
• In Parkinson’s disease cohorts, the intraclass correlation coefficient (ICC) for test-retest reliability over a 2-week interval was recorded at .84 (95% CI: .78–.89).
• In post-stroke cohorts, test-retest reliability across 1- to 3-week intervals yielded ICC values between .82 and .91.
• The Dutch adaptation demonstrated an ICC of .83 in MS patients assessed two weeks apart.

These findings substantiate that the FSS provides a highly stable baseline metric when clinical conditions are static, yet remains sensitive to authentic biological or therapeutic shifts.

9. Factor Analysis

Extensive exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) have examined the structural validity of the FSS, yielding critical psychometric insights into its latent structure.

Unidimensionality and Factor Loadings

In the majority of classical psychometric assessments, the FSS demonstrates an essentially unidimensional factor structure, wherein all nine items load onto a single dominant latent factor representing general fatigue severity and functional disruption. Early EFA studies utilizing principal axis factoring or principal component analysis typically identify a single eigenvalue exceeding Kaiser’s criterion (> 1.0), accounting for 55% to 70% of the total variance across clinical cohorts.

Typical standardized factor loadings from published confirmatory models are summarized below:

• Item 1 (Lower motivation): λ = .55 – .68
• Item 2 (Exercise brings fatigue): λ = .52 – .65
• Item 3 (Easily fatigued): λ = .72 – .82
• Item 4 (Interferes with physical functioning): λ = .81 – .89
• Item 5 (Causes frequent problems): λ = .82 – .90
• Item 6 (Prevents sustained physical functioning): λ = .84 – .91
• Item 7 (Interferes with duties/responsibilities): λ = .82 – .89
• Item 8 (Among three most disabling symptoms): λ = .68 – .78
• Item 9 (Interferes with work, family, social life): λ = .80 – .88

Items 4, 5, 6, 7, and 9 consistently show the highest loadings (> .80), indicating that the core of the latent trait corresponds to physical interference and disruption of instrumental roles.

Alternative Factor Solutions and Rasch Analyses

While unidimensionality is standardly accepted for clinical scoring, several contemporary psychometric investigations utilizing modern Item Response Theory (IRT) and Rasch analysis have noted potential local dependencies or multidimensional nuances. Specifically, Items 1 and 2 occasionally display lower item-scale correlations or bifactor tendencies:

• Item 1 (Motivation) relates to mental or motivational drive, which sometimes aligns partly with affective dimensions.
• Item 2 (Exercise) evaluates a specific triggering mechanism rather than daily disability.

Consequently, some researchers (e.g., Mills et al., 2009) proposed an abbreviated 7-item version (FSS-7), which excludes Items 1 and 2 to achieve strict Rasch unidimensional fit. Nevertheless, the original 9-item FSS remains the universally recognized, regulatory-accepted standard in clinical practice and international research protocols, exhibiting adequate CFA goodness-of-fit indices (CFI > .94, TLI > .92, RMSEA < .08) when minor residual covariances between physically related items are specified.

10. Instrument / Measurement Tool

• Name of Tool: Fatigue Severity Scale (FSS)
• Alternative Names: FSS-9
• Type of Instrument: Patient-Reported Outcome Measure (PROM); self-report questionnaire
• Target Population: Adults (≥ 18 years) and older adults diagnosed with chronic medical, neurological, or autoimmune disorders (e.g., Multiple Sclerosis, Systemic Lupus Erythematosus, Parkinson’s Disease, Stroke, Post-Viral Syndromes, Fibromyalgia); also applicable in non-clinical epidemiological cohorts.
• Administration Format: Pen-and-paper self-administration, digital/electronic survey (ePRO), or clinician-facilitated interview.
• Completion Time: Approximately 2 to 3 minutes.
• Number of Items: 9 items.
• Recall Period: Past week (the previous 7 days).
• Response Scale: 7-point Likert scale:
  • 1 = Strongly disagree
  • 2 = Disagree
  • 3 = Somewhat disagree
  • 4 = Neither agree nor disagree
  • 5 = Somewhat agree
  • 6 = Agree
  • 7 = Strongly agree
• Scoring Method:
  • All 9 items are positively framed with regard to fatigue severity; there are no reverse-scored items.
  • The Global FSS Score is computed as the arithmetic mean (average) across all 9 items:
    Total FSS Score = (Sum of Items 1 to 9) ÷ 9
  • Possible score range: 1.0 to 7.0.
  • (Alternative sum scoring method: Range 9 to 63; however, the mean score metric of 1.0 to 7.0 is predominantly preferred in academic literature).
• Cut-Off Scores & Clinical Interpretation:
  • Score < 4.0: Normal baseline / non-severe fatigue (characteristic of healthy individuals; mean normative values typically range from 2.3 to 3.0).
  • Score ≥ 4.0: Indicates clinically significant, pathological fatigue requiring clinical attention and intervention.
  • Score ≥ 5.0: Severe fatigue, causing substantial functional and occupational disability.

11. Permissions & Fee and Test Year

The Fatigue Severity Scale was first published in 1989 by Dr. Lauren B. Krupp and associates in the Archives of Neurology (now JAMA Neurology). The instrument was developed under academic and institutional research auspices supported in part by the National Multiple Sclerosis Society and the National Institutes of Health.

Licensing and Accessibility:

• The original 9-item instrument is widely considered to reside within the public domain for non-commercial academic research, clinical education, and routine individual patient care.
• Standard clinical utilization generally does not require formal licensing fees; however, investigators conducting sponsored commercial clinical trials or incorporating the scale into proprietary commercial software platforms are advised to seek appropriate clearance or check publisher copyright restrictions via the American Medical Association / JAMA Network.
• Users must consistently cite the original primary literature publication (Krupp et al., 1989) and any applicable validated language translations utilized in their protocols.

12. References

• Friedman, J. H., Alves, G., Hagell, P., Marinus, J., Marsh, L., Martinez-Martin, P., Goetz, C. G., Poewe, W., Rascol, O., Sampaio, C., Stebbins, G., & Schrag, A. (2010). Fatigue rating scales criticism for Parkinson’s disease: A task force report of the Movement Disorder Society. Movement Disorders, 25(7), 805–822. https://doi.org/10.1002/mds.22989
• Krupp, L. B., LaRocca, N. G., Muir-Nash, J., & Steinberg, A. D. (1989). The Fatigue Severity Scale: Application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology, 46(10), 1121–1123. https://doi.org/10.1001/archneur.1989.00520460115022
• Lerdal, A., Wahl, A., Rustøen, T., Hanestad, B. R., & Moum, T. (2005). Fatigue in the general population: A translation and test of the psychometric properties of the Norwegian version of the Fatigue Severity Scale. Scandinavian Journal of Public Health, 33(2), 123–130. https://doi.org/10.1080/14034940410028406
• Mills, R. J., Young, C. A., Pallant, J. F., & Tennant, A. (2009). Development of a unidimensional Fatigue Severity Scale for multiple sclerosis through Rasch analysis. Journal of the Neurological Sciences, 287(1-2), 184–189. https://doi.org/10.1016/j.jns.2009.07.030
• Rietberg, M. B., van Wegen, E. E. H., & Kwakkel, G. (2010). Measuring fatigue in patients with multiple sclerosis: Reproducibility, responsiveness and concurrent validity of three Dutch fatigue scales. Disability and Rehabilitation, 32(22), 1870–1876. https://doi.org/10.3109/09638281003734458
• Vercoulen, J. H., Swanink, C. M., Fennis, J. F., Galama, J. M., van der Meer, J. W., & Bleijenberg, G. (1996). Dimensional assessment of chronic fatigue syndrome. Journal of Psychosomatic Research, 41(5), 461–473. https://doi.org/10.1016/s0022-3999(96)00209-6

13. Items of the Scale